Understanding the Burden and Post-Discharge Management of Severe Malarial Anaemia and Severe Malaria Among Tanzanian Children: An Epidemiological and Qualitative Study (PODSMA-TZ)
This study will examine what happens to children aged 3 months to 5 years after hospital discharge following severe malaria or severe malarial anaemia (a very low blood level caused by malaria). It will take place at Newala District Hospital in Tanzania.
Researchers will review hospital records from the previous two years. They will also follow 250 children for 12 weeks after hospital discharge.
The study will examine:
- Whether children die or return to hospital after discharge.
- Whether children experience malaria again after discharge.
- How children's blood levels recover after severe illness.
- The healthcare services families use and the costs they face.
Researchers will also interview caregivers, community health workers and healthcare providers. These interviews will explore experiences, challenges and support available to children after hospital discharge.
The findings will help improve understanding of children's recovery after severe malaria. They may also inform future approaches to follow-up care and support for affected children.
This is an observational study. Researchers will not give participants any study medicine or additional treatment.
調査の概要
状態
状態
条件
条件
詳細な説明
PODSMA-TZ is a non-interventional, observational mixed-methods study conducted at Newala District Hospital, Mtwara Region, Tanzania. The study combines retrospective review of routine hospital records, prospective follow-up of children discharged after severe malaria or severe malarial anaemia (SMA), and qualitative research.
The retrospective component will review routinely collected hospital records from the preceding two years. Basic admission information will be abstracted for all children aged 3 months to 5 years to establish the denominator of paediatric admissions. More detailed demographic, clinical, laboratory, treatment and outcome information will be collected for children diagnosed with severe malaria or SMA according to World Health Organization criteria.
The prospective component will involve observational follow-up of eligible children after hospital discharge. Information will be collected on their health and recovery, healthcare utilisation, care-seeking practices and medication adherence. Healthcare-related costs and household expenditures associated with care will also be documented during follow-up.
The qualitative component will explore experiences and challenges associated with post-discharge care. Approximately 30 caregivers will participate in in-depth interviews. An estimated 20-25 healthcare providers will participate in key-informant interviews. Additionally, 4-6 focus group discussions will be conducted with community health workers, with 6-8 participants in each group.
Qualitative discussions will explore experiences of caring for children after severe malaria, barriers and facilitators to accessing follow-up care, malaria prevention practices, and awareness and perceptions of potential future post-discharge malaria chemoprevention (PDMC) and monoclonal antibody interventions. These discussions will also explore acceptability and readiness for possible future implementation of these approaches.
Interviews and focus group discussions will be audio-recorded with participants' consent, transcribed in Kiswahili and translated into English where required.
The study does not involve randomisation, allocation to intervention groups or administration of study treatments. Clinical care will continue according to routine healthcare practice.
研究の種類
研究の種類
入学 (推定)
入学
連絡先と場所
研究連絡先
研究連絡先
- 名前:Kamaka Ramadhani Kassimu, PhD
- 電話番号:+255713488238
- メール:kramadhani@ihi.or.tz
研究場所
-
-
Mtwara
-
Newala、Mtwara、タンザニア、63422
- Newala District Hospital
-
コンタクト:
- Kamaka R Kassimu, PhD
- 電話番号:+255713488238
- メール:kramadhani@ihi.or.tz
-
主任研究者:
- Kamaka R Kassimu, PhD
-
副調査官:
- Scolastica L Lusenge, MD
-
副調査官:
- Tunu H Ndanzi, Msc.
-
副調査官:
- Abdallah S Lusasi, MPH
-
副調査官:
- Hassan T Berenge, MA (PME)
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
Children aged 3 months to 5 years admitted with severe malaria or SMA at Newala District Hospital and followed after discharge; paediatric hospital admission records for the two-year retrospective review; and caregivers, healthcare providers and community health workers involved in post-discharge care in Newala District.
説明
Eligibility - Retrospective
Inclusion Criteria:
- All paediatric admissions aged 3 months to 5 years during the two-year review period contribute basic admission information; detailed clinical abstraction for records of children diagnosed with severe malaria or SMA according to WHO criteria.
Exclusion Criteria:
- Records outside age range; insufficient information to determine eligibility, diagnosis or outcome; inadequate documentation to confirm severe malaria or SMA. Eligibility - Prospective Cohort
Inclusion criteria:
- Child aged 3 months to 5 years; admitted with severe malaria or SMA; clinically stable for discharge; parent/legal guardian provides written informed consent.
Exclusion criteria:
- Declined/no consent; prior enrolment in prospective cohort; known chronic conditions requiring long-term specialised care (e.g., malignancy or severe congenital disease requiring tertiary management). Common co-existing conditions including severe acute malnutrition, HIV, sickle cell disease, pneumonia and sepsis are not exclusion criteria. Eligibility - Qualitative
- Caregivers of enrolled children, healthcare providers and community health workers. Participation is voluntary; individuals who decline or are unable to participate in Kiswahili without translation support are excluded.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 観測モデル:OTHER
- 時間の展望:OTHER
グループ/コホートの数
コホートと介入
グループ/コホートグループ/コホート |
|---|
|
Children discharged after severe malaria or severe malarial anaemia (prospective cohort).
Approximately 250 children aged 3 months to 5 years admitted with severe malaria or SMA, clinically stable for discharge and enrolled at discharge following written guardian consent. Follow-up at Weeks 1, 4, 8 and 12. No intervention or assigned exposure. |
|
Retrospective paediatric hospital records
Routinely collected records of all children aged 3 months to 5 years admitted during the preceding two-year review period provide denominator data. Detailed abstraction is undertaken for records of children diagnosed with severe malaria or SMA according to WHO criteria. This is a records-based component, not an intervention group. |
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
All-cause post-discharge mortality.
時間枠:Day 0 through Day 84 after discharge/enrolment.
|
Death from any cause during the 12-week post-discharge period, reported as the proportion of enrolled children who die. Day 0 is discharge/enrolment. |
Day 0 through Day 84 after discharge/enrolment.
|
|
Hospital readmission
時間枠:Day 0 through Day 84
|
One or more overnight rehospitalisations for any cause during the 12-week follow-up. Summarise the proportion with any readmission and total number of readmissions |
Day 0 through Day 84
|
|
Recurrent clinical malaria
時間枠:Day 0 through Day 84
|
Time to first recurrent malaria episode, defined as a positive malaria RDT or microscopy result accompanied by fever or history of fever |
Day 0 through Day 84
|
|
Anaemia recovery among children with SMA at baseline.
時間枠:Week 12 assessment; permitted visit window up to 7 days after Day 84 (Days 85-91).
|
Achievement of haemoglobin concentration ≥10 g/dL at the Week 12 assessment among participants with SMA at baseline. |
Week 12 assessment; permitted visit window up to 7 days after Day 84 (Days 85-91).
|
|
Haemoglobin trajectory
時間枠:Baseline/discharge through Weeks 1, 4, 8 and 12; Week 12 may occur within the permitted +7-day window.
|
Change in haemoglobin concentration across baseline and follow-up assessments. Baseline haemoglobin is the admission measurement if available; otherwise, the discharge/enrolment measurement is used. |
Baseline/discharge through Weeks 1, 4, 8 and 12; Week 12 may occur within the permitted +7-day window.
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Epidemiological and clinical patterns of severe malaria and severe malarial anaemia.
時間枠:Retrospective two-year record review; prospective admission through discharge for clinical/in-hospital outcomes, with post-discharge healthcare utilisation and costs assessed through Day 84 (12 weeks).
|
Distribution of admissions by age, sex and geographical origin; clinical/laboratory characteristics; parasite density where available; comorbidities; monthly and seasonal trends; and in-hospital outcomes. Healthcare utilisation and direct post-discharge healthcare costs will also be summarised. |
Retrospective two-year record review; prospective admission through discharge for clinical/in-hospital outcomes, with post-discharge healthcare utilisation and costs assessed through Day 84 (12 weeks).
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (推定)
研究開始
一次修了 (推定)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
キーワード
その他の研究ID番号
その他の研究ID番号
- 23540
- 337563 (その他の助成金/資金番号:GSK African Open Lab)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
To be confirmed by sponsor and PI. Protocol allows de-identified data sharing subject to institutional and applicable data-protection requirements but does not specify a formal public IPD-sharing commitment.
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。